Form 4: Xenon Pharmaceuticals CEO Ian Mortimer Granted Stock Options
SEC Form 4 Filing
Ian Mortimer, President and CEO of Xenon Pharmaceuticals, was granted stock options for 250,000 common shares on March 11, 2024.
Summary
- Ian Mortimer, the President and CEO of Xenon Pharmaceuticals, was granted stock options on March 11, 2024.
- The options are for 250,000 common shares with an exercise price of $44.37.
- The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
- The options expire on March 10, 2034.
- Mortimer also granted power of attorney to Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams to handle SEC filings related to his holdings in Xenon Pharmaceuticals.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it doesn't provide concrete information about the company's current financial health.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future value creation.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. This grant is a standard component of executive compensation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the CEO's interests with increasing shareholder value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of earliest transaction (grant of stock options) and execution of power of attorney. |
| 01/01/2025 | 25% of the stock options vest. |
| 03/10/2034 | Expiration date of the stock options. |
| 03/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.